Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Mumps
Research from Kaiser Permanente reveals new findings on mumps
April 30th, 2008
According to a study from the United States, "A quadrivalent vaccine combining measles, mumps, rubella, and varicella antigens ( MMRV) was developed to increase the coverage of varicella vaccine and reduce the number of injections children receive." "Although the varicella antigen is as immunogenic in the latest formulation of MMRV vaccine as when it is administered alone, up to 14% of vaccine recipients do not achieve protective levels of anti-varicella antibodies after a single dose, which can result in breakthrough varicella. A second dose of varicella vaccine raises response rates to 99% and was recently recommended by the Advisory Committee on Immunization...
Source: Vaccine Weekly (2008-04-30)
|
